Gapping down
In reaction to disappointing earnings/guidance: KMB -2.6%,
HAL -1.6%,
T -0.4%
Select EU financial related names showing weakness: LYG -4.1%,
DB -3.8%,
BCS -3.5%,
HSBC -1.9%,
ING -1%
Select oil/gas related names showing early weakness: SDRL -5.9%,
CHK -5.7%,
WLL -5.4%,
PBR -5.3%,
ETE -4.8%,
MRO -3%,
TOT -2.9%,
BP -2.4%,
COP -2.4%,
KMI -2.2%,
RIG -2.1%,
RDS.A -2%,
STO -1.6%,
SLB -1.5%,
XOM -1.4%
Other news: OMED -43% (updates on tarextumab phase 2 pancreatic cancer trial; DSMB recommended that the study proceed to completion without modification, but informed co of several findings regarding futility of the trial),
NVAX -7.9% (proposes offering of $200 mln of convertible senior notes due 2023),
MDVN -7.5% (discloses partial clinical hold on its IND for MDV9300),
TWTR -5.2% (confirms various executive departures),
MNKD -5.2% (modest pull back following Friday's move),
WMB -3% (announces 2016 Capital and Financing Plan; Funding needs of $2 bln, down approx $1 bln from prior plans),
ZFGN -2.7% (modest pull back following Friday's move),
ZINC -2.6% (temporarily idling its Mooresboro, North Carolina zinc production facility),
CEL -2.4% (announced the receipt of a labor dispute announcement by the Histadrut)
Analyst comments: KS -5.8% (downgraded to Underperform from Neutral at Macquarie),
WRK -5.2% (downgraded to Neutral from Buy at BofA/Merrill),
PKG -4.8% (downgraded to Neutral from Buy at Citigroup),
IP -4.5% (downgraded to Neutral from Buy at Citigroup),
CAT -3.7% (downgraded to Sell from Neutral at Goldman),
MOS -3.6% (downgraded to Neutral from Overweight at JP Morgan),
WFM -3% (downgraded to Underperform from Market Perform at BMO Capital),
POT -3% (downgraded to Neutral from Overweight at JP Morgan),
AEO -2.7% (downgraded to Hold from Buy at BB&T Capital Mkts),
REGN -2.7% (downgraded to Sell from Neutral at Chardan Capital Markets),
CMI -1.6% (downgraded to Neutral from Buy at Citigroup),
JPM -1% (downgraded to Neutral from Buy at Nomura)